Haddad J G, Walgate J
J Biol Chem. 1976 Aug 25;251(16):4803-9.
The binding protein for 25-hydroxycholecalciferol (25-OH-D3 or calcifidiol) in human plasma has been purified from Cohn Fraction IV. Following in vitro labeling with 25-OH-[3H]D3, the isolation sequence of procedures included: DEAE-cellulose chromatography; gel filtration on Sephadex G-200; chromatography on DEAE-Sephadex; preparative polyacrylamide gel electrophoresis. These procedures resulted in a calcifidiol-binding protein (Cal-BP) which had been purified approximately 170-fold, and which was homogeneous by physical and immunological criteria. The purified Cal-BP had inter-alpha mobility, a sedimentation constant (S20, w) of 3.46 S, and a molecular weight of approximately 59,000. Sucrose gradient ultracentrifugation of Cal-BP and ligand incubations indicated that there was apparently one binding site for either cholecalciferol, calcifidiol or 1,25-dihydroxycholecalciferol per molecule of human Cal-BP. The protein had highest affinity for calcifidiol, displaying an apparent dissociation constant (Kd) of 6.4 X 10(-8) M for this sterol. Specific anti-human Cal-BP antisera were prepared in rabbits, and produced precipitate lines of identity between Cal-BP and human serum. Specific binding of vitamin D3,25-OH-D3, and 1,25-(OH)2D3 by human serum was completely neutralized after immunoprecipitation of the serum with the gamma globulin fraction of anti-Cal-BP antiserum, indicating a common transport protein for these sterols in human plasma. There was no immunological cross-reactivity between Cal-BP and rat or chicken sera, indicating that the Cal-BP in these three sera are immunologically completely distinct. Purified human Cal-BP and human sera also produced lines of identity with commercial anti-human group-specific component (Gc) antisera in radial immunodiffusion experiments. This finding supports an earlier report of the identity of calciferol/calcifidiol-binding protein and group-specific component in human serum. The Cal-BP content of human serum is approximately 10(-5) M, whereas the calcifidiol content is approximately 10(-7) M. Normally, the dominant moiety of human plasma Cal-BP is the apoprotein.
人血浆中25-羟基胆钙化醇(25-OH-D3或骨化二醇)的结合蛋白已从Cohn第四组分中纯化出来。用25-OH-[3H]D3进行体外标记后,分离步骤顺序包括:二乙氨基乙基纤维素色谱法;葡聚糖凝胶G-200凝胶过滤;二乙氨基乙基葡聚糖凝胶色谱法;制备性聚丙烯酰胺凝胶电泳。这些步骤得到了一种骨化二醇结合蛋白(Cal-BP),其已被纯化约170倍,并且根据物理和免疫学标准是均一的。纯化的Cal-BP具有α间迁移率,沉降常数(S20,w)为3.46 S,分子量约为59,000。对Cal-BP和配体孵育物进行蔗糖梯度超速离心表明,每分子人Cal-BP对于胆钙化醇、骨化二醇或1,25-二羟基胆钙化醇显然有一个结合位点。该蛋白对骨化二醇具有最高亲和力,对这种固醇显示出表观解离常数(Kd)为6.4×10^(-8) M。在兔中制备了特异性抗人Cal-BP抗血清,并在Cal-BP和人血清之间产生了同一沉淀线。用人血清对维生素D3、25-OH-D3和1,25-(OH)2D3的特异性结合在用抗Cal-BP抗血清的γ球蛋白组分对血清进行免疫沉淀后被完全中和,表明在人血浆中这些固醇有共同的转运蛋白。Cal-BP与大鼠或鸡血清之间没有免疫交叉反应,表明这三种血清中的Cal-BP在免疫学上完全不同。在放射免疫扩散实验中,纯化的人Cal-BP和人血清与市售抗人组特异性成分(Gc)抗血清也产生了同一沉淀线。这一发现支持了早期关于人血清中胆钙化醇/骨化二醇结合蛋白与组特异性成分相同的报道。人血清中Cal-BP的含量约为10^(-5) M,而骨化二醇的含量约为10^(-7) M。正常情况下,人血浆Cal-BP的主要部分是载脂蛋白。